The company said it would work closely with the FDA to address the agency’s concerns, which the drugmaker expected to be communicated within the next 30 days. This is Sun Pharma’s second run-in with the FDA in less than two weeks.

Three years later, at least 65 million people worldwide are estimated to have long COVID, according to an evidence review published last month in Nature Reviews Microbiology. More than 200 symptoms have been linked to the syndrome – including extreme fatigue, difficulty thinking, headaches, dizziness when standing, sleep problems, chest pain, blood clots, immune dysregulation, and even diabetes.